| |
|
|
Session 105
Poster Presentations HCV: Therapeutic Progress Wednesday 1:30 - 3:30 pm Hall B |
| 841 | Final Results of Daily vs 3-times Weekly Interferon M. Sulkowski1, F. Felizarta2, J. Slim3, D. Dieterich4, R. Goodman*5, L. Ball5 1Johns Hopkins Med Inst, Baltimore, MD; 2Bakersfield, NJ; 3Newark, NJ; 4Mt Sinai Sch of Med, New York, NY; and 5Hepatitis Resource Network, Puyallup, WA |
| 842 | Predictive Value of Early Virological Response (12 Weeks) to Pegylated Interferon plus Ribavirin in HIV-HCV Co-infected Patients MAYTE PEREZ-OLMEDA*, LUZ MARTÍN-CARBONERO, PILAR RIOS RISQUEZ, MARINA NUÑEZ , JUAN GONZÁLEZ-LAHOZ, VICENTE SORIANO VAZQUEZ Hosp Carlos III, Madrid, Spain |
| 843 | Cost Impact of Adjunctive G-CSF and/or Darbopoetin Therapy in Maintenance of Pegylated-interferon Alpha and Ribavirin Doses in HIV/HCV Co-infected Patients A. Pau*1, A. Agyemang2, M. McLaughlin3, D. Suzman2, J. Metcalf3, C. Ternisky3, C. Koratich3, H. Masur1, M. Polis3, C. Daniels1, S. Kottilil3 1Clin Ctr, NIH, Bethesda, MD; 2Harvard Univ, Cambridge, MA; and 3Natl Inst of Allergy and Infectious Dis, NIH, Bethesda, MD |
| 844 | Serious Ophthalmologic Pathology with Visual Compromise in HIV/HCV Co-infected Patients Treated with Pegylated Interferon Alpha-2b and Ribavirin C. Farel*1, S. Kottilil1, M. McLaughlin1, C. Ternisky1, C. Koratich1, J. Kovacs2, J. Tavel1, R. Davey1, J. Falloon1, H. Masur2, J. Metcalf1, M. Robinson3, M. Polis1 1Natl Inst of Allergy and Infectious Diseases, NIH, Bethesda, MD; 2Clin Ctr, NIH, Bethesda, MD; and 3Natl Eye Inst, NIH, Bethesda, MD |
| 845 | A Genetic Screen to Monitor the Activity of the Hepatitis C Virus NS3 Serine Protease M. A. Martinez*, B. Clotet Fundacio IrsiCaixa Hosp Univ Germans Trias i Pujol, Barcelona, Spain |